FindTrial
Sign In

Trial for comparison of commonly used drug to the drug plus Calcium gluconate for measuring speed of recovery from muscle relaxant

Prospective randomized controlled trial for comparison of effect on neuromuscular blockade recovery between calcium gluconate coadministered with neostigmine and neostigmine only in pediatric patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026726
Enrollment
100
Registered
2020-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K929- Disease of digestive system, unspecified

Interventions

Intervention1: Neostigmine: Neostigmine will be administered as 70 microgram per kilogram of body weight stat dose as the reversal agent. Rest everything will be the same in both the groups Control I

Sponsors

Armed Forces Medical Research Comittee
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between age of 3 to 15 years 2. ASA I and II

Exclusion criteria

Exclusion criteria: 1. Suspected difficult airway 2. History of bronchial asthma, neuromuscular disease, hepatic or renal disease. 3. Clinically suspected hypercalcemia 4. Severe or significant congenital heart disease 5. Bleeding diathesis 6. History of allergies to glycopyrrolate or neostigmine 7. Parental refusal 8. Weight of less than 10 kg.

Design outcomes

Primary

MeasureTime frame
Duration between injecting reversal agent and TOFr more than 90% Timepoint: 3,5 and 10 min—

Secondary

MeasureTime frame
Post operative Recurarisation at 3,5 and 10 min interval of giving the reversal agentTimepoint: 3,5 and 10 min—

Countries

India

Contacts

Public ContactDr Gunjan Singh

Command Hospital Chandimandir

gunjanafmc@gmail.com09612112136

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026